ArticlePLoS neglected tropical diseases2025
Investigating HLA haplotypes as a potential risk factor for nodding syndrome: A case-control study in the Mahenge area, Tanzania.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nodding Syndrome: Shifting the Focus from Cause to Treatment.The American journal of tropical medicine and hygiene · 2026Review
- Nodding Syndrome: The Need to Strengthen Epilepsy Care in Onchocerciasis-Endemic Areas and to Investigate the Pathogenesis of Onchocerciasis-Associated Epilepsy.The American journal of tropical medicine and hygiene · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNodding syndrome (NS) is a disabling childhood-onset epilepsy occurring in onchocerciasis-endemic regions. High Onchocerca volvulus microfilarial loads in childhood are a key risk factor, but not all heavily infected individuals develop NS, suggesting a possible role for host genetic susceptibility. Human leukocyte antigen (HLA) haplotypes have been implicated in susceptibility to various infectious and autoimmune diseases, including onchocerciasis. We investigated potential associations between HLA haplotypes and onchocerciasis-associated epilepsy (OAE), including NS, in Tanzania.
methodsA case-control study was conducted in an onchocerciasis-endemic area in the Mahenge area, Tanzania, including 98 persons with epilepsy and 112 controls. DNA was extracted from dry blood spots and HLA sequence-based typing was performed by Histogenetics (Ossining, USA). A total of 11 HLA loci (HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1, and -DPB1) were exon sequenced. The HLA-typed dataset was analysed using pyHLA, including Bonferroni as multi-test adjustment, to test for associations with O. volvulus anti-Ov16 seropositivity, epilepsy, OAE and NS.
resultsAnti-Ov16 seropositivity was significantly higher in cases than controls (76.5% vs 58.9%; p = 0.01). No HLA alleles were significantly associated with epilepsy, OAE, NS, or anti-Ov16 seropositivity after correction. Before adjustment, HLA-C07:01 appeared to be a risk factor for epilepsy, HLA-DQB106:02 was associated with OAE, HLA-B35:01 with NS, and HLA-C08:02 and DRB1*03:01 with anti-Ov16 seropositivity. Post-hoc power analysis indicated that substantially larger sample sizes would be required to confirm these associations.
conclusionsThis study did not identify statistically significant HLA associations with epilepsy, OAE, NS, or O. volvulus exposure. However, several alleles-particularly HLA-B*35:01, also reported in a previous South Sudanese study-emerged as potential candidates for further investigation. Larger, multi-country studies with sufficient power are needed to clarify whether host genetic factors contribute to susceptibility to OAE and NS. Strengthening onchocerciasis elimination programmes remains essential, as NS is a preventable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.